

- H, Denk H, Trauner M. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. *Am J Pathol.* 2006; 168(2):410-22. doi: 10.2353/ajpath.2006.050404. PubMed PMID: 16436656; PMCID: PMC1606500.
- [0239] 96. Constantinou C, Henderson N, Iredale J P. Modeling liver fibrosis in rodents. *Methods Mol Med.* 2005; 117:237-50. doi: 10.1385/1-59259-940-0:237. PubMed PMID: 16118456.
- [0240] 97. Levine J H, Simonds E F, Bendall S C, Davis K L, Amir el A D, Tadmor M D, Litvin O, Fienberg H G, Jager A, Zunder E R, Finck R, Gedman A L, Radtke I, Downing J R, Pe'er D, Nolan G P. Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. *Cell.* 2015; 162(1):184-97. doi: 10.1016/j.cell.2015.05.047. PubMed PMID: 26095251; PMCID: PMC4508757.
- [0241] 98. Tsai J, Lee J T, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass N K, Sproesser K, Li L, Smalley K S, Fong D, Zhu Y L, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim S H, Schlessinger J, Zhang K Y, West B L, Powell B, Habets G, Zhang C, Ibrahim P N, Hirth P, Artis D R, Herlyn M, Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. *Proceedings of the National Academy of Sciences of the United States of America.* 2008; 105(8):3041-6. doi: 10.1073/pnas.0711741105. PubMed PMID: 18287029; PMCID: PMC2268581.
- [0242] 99. Lito P, Pratillas C A, Joseph E W, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong W L, Callahan M K, Merghoub T, Wolchok J D, de Stanchina E, Chandrarlapathy S, Poulikakos P I,
- [0243] 100. Poulikakos P I, Zhang C, Bollag G, Shokat K M, Rosen N. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. *Cancer Cell.* 2012; 22(5):668-82. doi: 10.1016/j.ccr.2012.10.009. PubMed PMID: 23153539; PMCID: PMC3713778.
- [0244] 100. Poulikakos P I, Zhang C, Bollag G, Shokat K M, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. *Nature.* 2010; 464(7287):427-30. doi: 10.1038/nature08902. PubMed PMID: 20179705; PMCID: PMC3178447.
- [0245] 101. Haroche J, Cohen-Aubart F, Emile J F, Donadieu J, Amoura Z. Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. *Journal of the American Academy of Dermatology.* 2015; 73(1):e29-30. doi: 10.1016/j.jaad.2014.10.045. PubMed PMID: 26089069.
- [0246] 102. Haroche J, Cohen-Aubart F, Emile J F, Maksud P, Drier A, Toledano D, Barete S, Charlotte F, Cluzel P, Donadieu J, Benameur N, Grenier P A, Besnard S, Ory J P, Lifermann F, Idbaih A, Granel B, Graffin B, Hervier B, Arnaud L, Amoura Z. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology.* 2015; 33(5): 411-8. doi: 10.1200/JCO.2014.57.1950. PubMed PMID: 25422482.
- [0247] 103. Tzoulis C, Schwarzlmuller T, Gjerde T O, Softeland E, Neckermann G, Biermann M, Haroche J, Straume O, Vintermyr O K. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. *BMC Res Notes.* 2015; 8:171. doi: 10.1186/s13104-015-1135-7. PubMed PMID: 25926131; PMCID: PMC4450489.
- [0248] 104. Vanden Bone P, Gunda V, McFadden D G, Sadow P M, Varmeh S, Bernasconi M, Parangi S. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. *Oncotarget.* 2014; 5(12): 3996-4010. doi: 10.1863/oncotarget.2130. PubMed PMID: 24994118; PMCID: PMC4147301.
- [0249] 105. Chakravarty D, Santos E, Ryder M, Knauf J A, Liao X H, West B L, Bollag G, Kolesnick R, Thin T H, Rosen N, Zanzonico P, Larson S M, Refetoff S, Ghossein R, Fagin J A. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. *The Journal of clinical investigation.* 2011; 121(12):4700-11. doi: 10.1172/JCI46382. PubMed PMID: 22105174; PMCID: PMC3225989.
- [0250] 106. Rochet N M, Kottschade L A, Markovic S N. Vemurafenib for melanoma metastases to the brain. *The New England journal of medicine.* 2011; 365(25):2439-41. doi: 10.1056/NEJMca1111672. PubMed PMID: 22188003.
- [0251] 107. Larkin J, Ascierto P A, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak M A, Chang I,
- [0252] 108. Choong N, Hack S P, McArthur G A, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *The New England journal of medicine.* 2014; 371(20):1867-76. doi: 10.1056/NEJMoa1408868. PubMed PMID: 25265494.
- [0253] 108. Allen C E, Li L, Peters T L, Leung H C, Yu A, Man T K, Gurusiddappa S, Phillips M T, Hicks M J, Gaikwad A, Merad M, McClain K L. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. *Journal of immunology.* 2010; 184(8):4557-67. doi: 10.4049/jimmuno.1.0902336. PubMed PMID: 20220088; PMCID: PMC3142675.
- [0254] 109. Egeler R M, Favara B E, van Meurs M, Laman J D, Claassen E. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. *Blood.* 1999; 94(12):4195-201. PubMed PMID: 10590064.
- [0255] 110. Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, Ghillani-Dalbin P, Hervier B, Kahn J E, Deback C, Musset L, Amoura Z, Haroche J. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. *Blood.* 2011; 117(10):2783-90. doi: 10.1182/blood-2010-10-313510. PubMed PMID: 21205927.
- [0256] 111. Sevcikova S, Kubiczkova L, Sedlarikova L, Rihova L, Kryukov F, Szturz P, Hajek R, Pour L, Adam Z. Impact of anakinra treatment on cytokine and lymphocytes/monocytes profile of an Erdheim-Chester patient. *Klin Onkol.* 2014; 27(4):276-82. PubMed PMID: 25115717.